Nanoparticle-Based Drug Delivery System: A Patient-Friendly Chemotherapy for Oncology

Yan, Lingling; Shen, Jingjing; Wang, Jinqiao; Yang, Xiaoyan; Dong, Shiyan; Lu, Saijun

doi:10.1177/1559325820936161

Cited by 125 publications

(81 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The trial performed by Kaklamani et al showed a pCR of 17.9%, a result similar to a previously reported clinical trial that used lapatinib in combination with weekly paclitaxel in women with inflammatory breast cancer, however, it showed a decrease in grade 3 diarrhea [20,35]. The use of abraxane has also been reported to improve overall response and survival, as well as to decrease hypersensitivity reactions, reducing the use of corticosteroids in advance [36]. The trial performed by Yardley et al reported a lower overall response rate in comparison to similar studies.…”

Section: Discussionsupporting

confidence: 73%

Nanomedicine Interventions in Clinical Trials for the Treatment of Metastatic Breast Cancer

et al. 2021

View full text Add to dashboard Cite

Breast cancer was responsible for the deaths of 626,679 women in 2018. After decades of research, the mortality rates remain high. While the barrier of selectively killing tumor cells is not yet overcome, the search for targeted therapeutics continues. The use of nanomedicine in cancer treatment has opened up new possibilities for more precise drug-delivery systems. This review aimed to gather information and analyze recent clinical trials evaluating the therapeutic effects of nanoparticles in the treatment of metastatic breast cancer. To accomplish this, the clinicaltrials.gov database was consulted, and after employing specific exclusion criteria, 11 clinical trials were selected. Nanoparticle albumin-stabilized paclitaxel was evaluated in ten clinical trials and paclitaxel-incorporating polymeric micelles were assessed in one clinical trial. Overall, this review confirmed a clinical benefit in the use of nanoparticle albumin-stabilized paclitaxel for the treatment of breast cancer, with reduced toxicity when compared to first-line treatments. Three studies did not meet the primary endpoint, however, and so the authors advised further evaluations. Although the use of nanomedicine is revolutionizing the cancer field, to integrate this regimen into generalized clinical treatment, additional clinical trials must be performed to achieve a favorable safety and efficacy profile.

show abstract

Section: Discussionsupporting

confidence: 73%

Nanomedicine Interventions in Clinical Trials for the Treatment of Metastatic Breast Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This allows for an understanding of why the concerted inhibition of NHE1 plus CA inhibitors improves the efficacy of paclitaxel by mediating its induction of apoptosis in triple-negative BC cells and its metastases [ 44 , 46 , 52 , 139 , 167 , 179 , 202 , 239 , 241 , 247 , 248 ]. More recently, liposomal preparations and nanodrugs of DOXO and others compounds have been trying to find a place in the treatment of BC and other tumors, and clinical trials with these methodologies are underway [ 249 ].…”

Section: Other Ph-related Available Therapies In Breast Cancer Trementioning

confidence: 99%

Towards an Integral Therapeutic Protocol for Breast Cancer Based upon the New H+-Centered Anticancer Paradigm of the Late Post-Warburg Era

Harguindey¹,

Alfarouk

Orozco³

et al. 2020

IJMS

View full text Add to dashboard Cite

A brand new approach to the understanding of breast cancer (BC) is urgently needed. In this contribution, the etiology, pathogenesis, and treatment of this disease is approached from the new pH-centric anticancer paradigm. Only this unitarian perspective, based upon the hydrogen ion (H+) dynamics of cancer, allows for the understanding and integration of the many dualisms, confusions, and paradoxes of the disease. The new H+-related, wide-ranging model can embrace, from a unique perspective, the many aspects of the disease and, at the same time, therapeutically interfere with most, if not all, of the hallmarks of cancer known to date. The pH-related armamentarium available for the treatment of BC reviewed here may be beneficial for all types and stages of the disease. In this vein, we have attempted a megasynthesis of traditional and new knowledge in the different areas of breast cancer research and treatment based upon the wide-ranging approach afforded by the hydrogen ion dynamics of cancer. The concerted utilization of the pH-related drugs that are available nowadays for the treatment of breast cancer is advanced.

show abstract

“…This allows understanding why the concerted inhibition of NHE1 plus CA inhibitors improves the efficacy of Paclitaxel by mediating in its induction of apoptosis in triple-negative BC cells and its metastases [36,38,44,128,156,168,192,230,232,238,239]. More recently, liposomal preparations and nanodrugs of DOXO and others compounds are trying to find a place in the treatment of BC and other tumors, and clinical trials with these methodologies are under way [240].…”

Section: Doxorubicin (Doxo) and Paclitaxelmentioning

confidence: 99%

Towards An Integral Therapeutic Protocol for Breast Cancer based upon the New H+-Centered Anticancer Paradigm of the Late Post-Warburg Era

Harguindey¹,

Alfarouk

Orozco³

et al. 2020

Preprint

View full text Add to dashboard Cite

A brand-new approach to the understanding of breast cancer (BC) is urgently needed. In this contribution, the etiology, pathogenesis, and treatment of this disease is approached from the new pH-centric anticancer paradigm. Only this Unitarian perspective based upon that the hydrogen ion (H+) dynamics of cancer, allows understanding and integrating the many dualisms, confusions, and paradoxes of the disease. The new H+-related wide range model can embrace under a unique frame of mind the many aspects of the disease and at the same time therapeutically interfere with most, if not with all, the hallmarks of cancer known to date. The pH-related armamentarium available for the treatment of BC here reviewed may be beneficial for all types and stages of the disease. In this vein, we have attempted a mega synthesis of traditional and new knowledge in the different areas of breast cancer research and treatment based upon the wide range approach afforded by the hydrogen ion dynamics of cancer. The concerted utilization of a pH-related drugs nowadays available for the treatment of breast cancer is advanced.

show abstract

Nanoparticle-Based Drug Delivery System: A Patient-Friendly Chemotherapy for Oncology

Cited by 125 publications

References 126 publications

Nanomedicine Interventions in Clinical Trials for the Treatment of Metastatic Breast Cancer

Nanomedicine Interventions in Clinical Trials for the Treatment of Metastatic Breast Cancer

Towards an Integral Therapeutic Protocol for Breast Cancer Based upon the New H+-Centered Anticancer Paradigm of the Late Post-Warburg Era

Towards An Integral Therapeutic Protocol for Breast Cancer based upon the New H+-Centered Anticancer Paradigm of the Late Post-Warburg Era

Contact Info

Product

Resources

About